Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Yu on Trials of Moderate Hypofractionation in Prostate Cancer

James B. Yu, MD
Published: Tuesday, Apr 11, 2017



James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

The results of the RTOG-0415 trial, presented by W. Robert Lee, MD, during the 2016 Genitourinary Cancers Symposium, showed that hypofractionation was equivalent and noninferior to the control. The PROFIT study showed similar results.

Additionally, Yu says that there is a chance for a slight rise in toxicities, which is attributed to the radiation being given faster.
 


James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

The results of the RTOG-0415 trial, presented by W. Robert Lee, MD, during the 2016 Genitourinary Cancers Symposium, showed that hypofractionation was equivalent and noninferior to the control. The PROFIT study showed similar results.

Additionally, Yu says that there is a chance for a slight rise in toxicities, which is attributed to the radiation being given faster.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x